Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

REALM THERAPEUTICS PLC (PURI)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 08/14 11:27:35 am
22 GBp   -45.00%
08:21aREALM THERAPEUT : Half-year Report
PU
08/08REALM THERAPEUT : Presents at Wedbush PacGrow Healthcare Conference
PU
08/07REALM THERAPEUT : Notice of Results
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Realm Therapeutics : Result of AGM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2018 | 12:08pm CEST

Realm Therapeutics Announces Results of 2018 Annual General Meeting

MALVERN, PA, June 14, 2018- Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announcesthat all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's website at www.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.

RNS-RLM

Contacts:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

Argot Partners

Stephanie Marks / Susan Kim

+1 212 600 1902

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

Disclaimer

Realm Therapeutics plc published this content on 14 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 14 June 2018 10:07:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REALM THERAPEUTICS PLC
08:21aREALM THERAPEUTICS : Half-year Report
PU
08/08REALM THERAPEUTICS : Presents at Wedbush PacGrow Healthcare Conference
PU
08/07REALM THERAPEUTICS : Notice of Results
PU
07/14REALM THERAPEUTICS : Announces Publication of Pre-Clinical Study Demonstrating C..
AQ
07/12REALM THERAPEUTICS : Announces U.S. SEC Declares Registration Statement Effectiv..
AQ
07/10REALM THERAPEUTICS : Pre-Clinical Study in Atopic Dermatitis
PU
07/05REALM THERAPEUTICS : Patent Issued for Methods and Compositions for Treating Inf..
AQ
07/04REALM THERAPEUTICS : Instructions for Exchanging Ordinary Shares
PU
07/04REALM THERAPEUTICS : SEC registration effective NASDAQ listing approved
PU
06/28REALM THERAPEUTICS : Patent Issued for Methods and Compositions for Treating Inf..
AQ
More news
Financials (GBP)
Sales 2018 0,81 M
EBIT 2018 -
Net income 2018 -
Finance 2018 15,5 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 38,4x
EV / Sales 2019 54,8x
Capitalization 46,6 M
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REALM THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Christian Peters Chief Medical Officer
Joseph William Birkett Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC8.11%60
CELLTRION, INC.--.--%28 909
IQVIA HOLDINGS INC23.75%24 543
LONZA GROUP21.15%23 934
INCYTE CORPORATION-31.96%13 698
SEATTLE GENETICS, INC.37.94%11 644